Heat Biologics records biggest one-day gain in over four months

66
10
Favorite

Heat Biologics records biggest one-day gain in over four months

seekingalpha2021-06-11

Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today. Last week, the company updated Phase 2 data for its off-the-shelf, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（10）

CWJ
·2021-06-11
?
Reply
Like
Report
CWJ
·2021-06-11
?
Reply
Like
Report
Jonhuatah
·2021-06-11
Wow serious
Reply
Like
Report
SalTheFun
·2021-06-11
Waited for this
Reply
Like
Report
DELFINO
·2021-06-11
:o
Reply
2
Report
BeBob
·2021-06-11
Like thanks
Reply
1
Report
Fold Replies
- skyel:
  Please like and comment please. Thanks
  2021-06-11
  Reply
  Report
ycwoo
·2021-06-11
Comment pls
Reply
1
Report
Fold Replies
- DELFINO:
  :o
  2021-06-11
  Reply
  Report
HOTBE
·2021-06-11
Potential to growth!
Reply
Like
Report
Fold Replies
- HOTBE:
  ???
  2021-06-11
  Reply
  Report
- Noobinvestor:
  Yes
  2021-06-11
  Reply
  Report
Fredwkh
·2021-06-11
Like and comment pls
Reply
3
Report
Fold Replies
- Fredwkh:
  Thanks
  2021-06-12
  Reply
  Report
- YH17:
  done.
  please do the same.
  2021-06-11
  Reply
  Report
LongZR
·2021-06-11
Nice like comment
Reply
2
Report
Fold Replies
- LongZR:
  nice
  2021-06-11
  Reply
  Report
- Glenna:
  good
  2021-06-11
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1145078337?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-11 08:01","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1145078337","market":"us","top_or_hot":-1,"title":"Heat Biologics records biggest one-day gain in over four months","media":"seekingalpha","content":"<div>\n<p>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heat Biologics records biggest one-day gain in over four months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeat Biologics records biggest one-day gain in over four months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months","article_id":"1145078337","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145078337","pubTimestamp":1623369715,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a ne","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Heat Biologics创四个月来最大单日涨幅","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HTBX":0.9},"content_text":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, allogeneic cell therapy HS-110 in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).\nIn previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.\nmOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.\n“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.\n“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”\nHeat Biologics announced positive interim data from the trial in February.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":181444629,"gmtCreate":1623409256261,"gmtModify":1704202808244,"author":{"id":"3558675003296714","authorId":"3558675003296714","name":"CWJ","avatar":"https://static.tigerbbs.com/9937d56ebf8e20a8ef7da0b626eeaddd","vip":1,"crmLevel":4,"crmLevelSwitch":1},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181444629","repostId":1145078337,"repostType":4,"repost":{"id":"1145078337","pubTimestamp":1623369715,"share":"https://www.laohu8.com/m/news/1145078337?lang=&edition=full","pubTime":"2021-06-11 08:01","market":"us","language":"en","title":"Heat Biologics records biggest one-day gain in over four months","url":"https://stock-news.laohu8.com/highlight/detail?id=1145078337","media":"seekingalpha","summary":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a ne","content":"<ul>\n <li>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.</li>\n <li>Last week, the company updated Phase 2 data for its off-the-shelf,&nbsp;allogeneic cell therapy HS-110&nbsp;in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).</li>\n <li>In previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.</li>\n <li>mOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.</li>\n <li>“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.</li>\n <li>“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”</li>\n <li>Heat Biologics announced positive interim data&nbsp;from the trial in February.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heat Biologics records biggest one-day gain in over four months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeat Biologics records biggest one-day gain in over four months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1145078337","content_text":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, allogeneic cell therapy HS-110 in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).\nIn previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.\nmOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.\n“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.\n“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”\nHeat Biologics announced positive interim data from the trial in February.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181444932,"gmtCreate":1623409242426,"gmtModify":1704202807588,"author":{"id":"3558675003296714","authorId":"3558675003296714","name":"CWJ","avatar":"https://static.tigerbbs.com/9937d56ebf8e20a8ef7da0b626eeaddd","vip":1,"crmLevel":4,"crmLevelSwitch":1},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181444932","repostId":1145078337,"repostType":4,"repost":{"id":"1145078337","pubTimestamp":1623369715,"share":"https://www.laohu8.com/m/news/1145078337?lang=&edition=full","pubTime":"2021-06-11 08:01","market":"us","language":"en","title":"Heat Biologics records biggest one-day gain in over four months","url":"https://stock-news.laohu8.com/highlight/detail?id=1145078337","media":"seekingalpha","summary":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a ne","content":"<ul>\n <li>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.</li>\n <li>Last week, the company updated Phase 2 data for its off-the-shelf,&nbsp;allogeneic cell therapy HS-110&nbsp;in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).</li>\n <li>In previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.</li>\n <li>mOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.</li>\n <li>“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.</li>\n <li>“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”</li>\n <li>Heat Biologics announced positive interim data&nbsp;from the trial in February.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heat Biologics records biggest one-day gain in over four months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeat Biologics records biggest one-day gain in over four months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1145078337","content_text":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, allogeneic cell therapy HS-110 in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).\nIn previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.\nmOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.\n“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.\n“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”\nHeat Biologics announced positive interim data from the trial in February.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181638267,"gmtCreate":1623388922859,"gmtModify":1704202317803,"author":{"id":"3581969780023175","authorId":"3581969780023175","name":"Jonhuatah","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Wow serious","listText":"Wow serious","text":"Wow serious","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181638267","repostId":1145078337,"repostType":4,"repost":{"id":"1145078337","pubTimestamp":1623369715,"share":"https://www.laohu8.com/m/news/1145078337?lang=&edition=full","pubTime":"2021-06-11 08:01","market":"us","language":"en","title":"Heat Biologics records biggest one-day gain in over four months","url":"https://stock-news.laohu8.com/highlight/detail?id=1145078337","media":"seekingalpha","summary":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a ne","content":"<ul>\n <li>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.</li>\n <li>Last week, the company updated Phase 2 data for its off-the-shelf,&nbsp;allogeneic cell therapy HS-110&nbsp;in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).</li>\n <li>In previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.</li>\n <li>mOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.</li>\n <li>“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.</li>\n <li>“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”</li>\n <li>Heat Biologics announced positive interim data&nbsp;from the trial in February.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heat Biologics records biggest one-day gain in over four months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeat Biologics records biggest one-day gain in over four months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1145078337","content_text":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, allogeneic cell therapy HS-110 in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).\nIn previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.\nmOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.\n“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.\n“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”\nHeat Biologics announced positive interim data from the trial in February.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181882654,"gmtCreate":1623384856678,"gmtModify":1704202208022,"author":{"id":"3579809773434763","authorId":"3579809773434763","name":"SalTheFun","avatar":"https://static.tigerbbs.com/69c72146aa04d3efddd999f936505379","vip":1,"crmLevel":8,"crmLevelSwitch":1},"htmlText":"Waited for this","listText":"Waited for this","text":"Waited for this","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181882654","repostId":1145078337,"repostType":2,"repost":{"id":"1145078337","pubTimestamp":1623369715,"share":"https://www.laohu8.com/m/news/1145078337?lang=&edition=full","pubTime":"2021-06-11 08:01","market":"us","language":"en","title":"Heat Biologics records biggest one-day gain in over four months","url":"https://stock-news.laohu8.com/highlight/detail?id=1145078337","media":"seekingalpha","summary":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a ne","content":"<ul>\n <li>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.</li>\n <li>Last week, the company updated Phase 2 data for its off-the-shelf,&nbsp;allogeneic cell therapy HS-110&nbsp;in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).</li>\n <li>In previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.</li>\n <li>mOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.</li>\n <li>“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.</li>\n <li>“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”</li>\n <li>Heat Biologics announced positive interim data&nbsp;from the trial in February.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heat Biologics records biggest one-day gain in over four months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeat Biologics records biggest one-day gain in over four months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1145078337","content_text":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, allogeneic cell therapy HS-110 in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).\nIn previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.\nmOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.\n“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.\n“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”\nHeat Biologics announced positive interim data from the trial in February.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181959967,"gmtCreate":1623371505359,"gmtModify":1704201827807,"author":{"id":"3574333394490724","authorId":"3574333394490724","name":"DELFINO","avatar":"https://static.tigerbbs.com/44e9ea498f962da1d7752be58a3802df","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":":o","listText":":o","text":":o","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181959967","repostId":1145078337,"repostType":4,"repost":{"id":"1145078337","pubTimestamp":1623369715,"share":"https://www.laohu8.com/m/news/1145078337?lang=&edition=full","pubTime":"2021-06-11 08:01","market":"us","language":"en","title":"Heat Biologics records biggest one-day gain in over four months","url":"https://stock-news.laohu8.com/highlight/detail?id=1145078337","media":"seekingalpha","summary":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a ne","content":"<ul>\n <li>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.</li>\n <li>Last week, the company updated Phase 2 data for its off-the-shelf,&nbsp;allogeneic cell therapy HS-110&nbsp;in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).</li>\n <li>In previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.</li>\n <li>mOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.</li>\n <li>“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.</li>\n <li>“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”</li>\n <li>Heat Biologics announced positive interim data&nbsp;from the trial in February.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heat Biologics records biggest one-day gain in over four months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeat Biologics records biggest one-day gain in over four months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1145078337","content_text":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, allogeneic cell therapy HS-110 in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).\nIn previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.\nmOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.\n“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.\n“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”\nHeat Biologics announced positive interim data from the trial in February.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181928873,"gmtCreate":1623371204392,"gmtModify":1704201818187,"author":{"id":"3585307651801295","authorId":"3585307651801295","name":"BeBob","avatar":"https://static.tigerbbs.com/4c7fb1588c34a61b54c3059c16e50b4e","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like thanks&nbsp;","listText":"Like thanks&nbsp;","text":"Like thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181928873","repostId":1145078337,"repostType":4,"repost":{"id":"1145078337","pubTimestamp":1623369715,"share":"https://www.laohu8.com/m/news/1145078337?lang=&edition=full","pubTime":"2021-06-11 08:01","market":"us","language":"en","title":"Heat Biologics records biggest one-day gain in over four months","url":"https://stock-news.laohu8.com/highlight/detail?id=1145078337","media":"seekingalpha","summary":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a ne","content":"<ul>\n <li>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.</li>\n <li>Last week, the company updated Phase 2 data for its off-the-shelf,&nbsp;allogeneic cell therapy HS-110&nbsp;in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).</li>\n <li>In previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.</li>\n <li>mOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.</li>\n <li>“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.</li>\n <li>“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”</li>\n <li>Heat Biologics announced positive interim data&nbsp;from the trial in February.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heat Biologics records biggest one-day gain in over four months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeat Biologics records biggest one-day gain in over four months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1145078337","content_text":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, allogeneic cell therapy HS-110 in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).\nIn previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.\nmOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.\n“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.\n“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”\nHeat Biologics announced positive interim data from the trial in February.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4675512,"gmtCreate":1623372137540,"gmtModify":1663228411049,"authorId":3581505866102985,"author":{"id":3581505866102985,"authorId":3581505866102985,"name":"skyel","avatar":"https://static.tigerbbs.com/a4e416c9b1fabad56fbe0e086388d5b0","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181928873,"type":1,"supId":0,"prevId":0,"content":"Please like and comment please. Thanks","text":"Please like and comment please. Thanks","html":"Please like and comment please. Thanks"}],"langContent":"EN"},{"id":181960514,"gmtCreate":1623370747138,"gmtModify":1704201798123,"author":{"id":"3565146699964497","authorId":"3565146699964497","name":"ycwoo","avatar":"https://community-static.tradeup.com/news/2f48b4bbc66c0bf509f7199142c1a2f2","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1},"htmlText":"Comment pls","listText":"Comment pls","text":"Comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181960514","repostId":1145078337,"repostType":4,"repost":{"id":"1145078337","pubTimestamp":1623369715,"share":"https://www.laohu8.com/m/news/1145078337?lang=&edition=full","pubTime":"2021-06-11 08:01","market":"us","language":"en","title":"Heat Biologics records biggest one-day gain in over four months","url":"https://stock-news.laohu8.com/highlight/detail?id=1145078337","media":"seekingalpha","summary":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a ne","content":"<ul>\n <li>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.</li>\n <li>Last week, the company updated Phase 2 data for its off-the-shelf,&nbsp;allogeneic cell therapy HS-110&nbsp;in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).</li>\n <li>In previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.</li>\n <li>mOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.</li>\n <li>“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.</li>\n <li>“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”</li>\n <li>Heat Biologics announced positive interim data&nbsp;from the trial in February.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heat Biologics records biggest one-day gain in over four months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeat Biologics records biggest one-day gain in over four months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1145078337","content_text":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, allogeneic cell therapy HS-110 in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).\nIn previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.\nmOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.\n“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.\n“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”\nHeat Biologics announced positive interim data from the trial in February.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4675234,"gmtCreate":1623371513937,"gmtModify":1663228408425,"authorId":3574333394490724,"author":{"id":3574333394490724,"authorId":3574333394490724,"name":"DELFINO","avatar":"https://static.tigerbbs.com/44e9ea498f962da1d7752be58a3802df","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181960514,"type":1,"supId":0,"prevId":0,"content":":o","text":":o","html":":o"}],"langContent":"EN"},{"id":181989998,"gmtCreate":1623370450814,"gmtModify":1704201784141,"author":{"id":"3576325295778787","authorId":"3576325295778787","name":"HOTBE","avatar":"https://static.tigerbbs.com/4f535d0d25c5b9833a0f75cd652fbbcd","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Potential to growth!","listText":"Potential to growth!","text":"Potential to growth!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/181989998","repostId":1145078337,"repostType":4,"repost":{"id":"1145078337","pubTimestamp":1623369715,"share":"https://www.laohu8.com/m/news/1145078337?lang=&edition=full","pubTime":"2021-06-11 08:01","market":"us","language":"en","title":"Heat Biologics records biggest one-day gain in over four months","url":"https://stock-news.laohu8.com/highlight/detail?id=1145078337","media":"seekingalpha","summary":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a ne","content":"<ul>\n <li>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.</li>\n <li>Last week, the company updated Phase 2 data for its off-the-shelf,&nbsp;allogeneic cell therapy HS-110&nbsp;in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).</li>\n <li>In previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.</li>\n <li>mOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.</li>\n <li>“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.</li>\n <li>“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”</li>\n <li>Heat Biologics announced positive interim data&nbsp;from the trial in February.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heat Biologics records biggest one-day gain in over four months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeat Biologics records biggest one-day gain in over four months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1145078337","content_text":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, allogeneic cell therapy HS-110 in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).\nIn previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.\nmOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.\n“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.\n“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”\nHeat Biologics announced positive interim data from the trial in February.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4674798,"gmtCreate":1623370539661,"gmtModify":1663228409028,"authorId":3576325295778787,"author":{"id":3576325295778787,"authorId":3576325295778787,"name":"HOTBE","avatar":"https://static.tigerbbs.com/4f535d0d25c5b9833a0f75cd652fbbcd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181989998,"type":1,"supId":4674777,"prevId":0,"content":"???","text":"???","html":"???"},{"id":4674777,"gmtCreate":1623370471004,"gmtModify":1663228408064,"authorId":3554471257802962,"author":{"id":3554471257802962,"authorId":3554471257802962,"name":"Noobinvestor","avatar":"https://static.tigerbbs.com/9648b4322bd8215633fa97bf7c443fd1","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.10%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181989998,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"EN"},{"id":181936040,"gmtCreate":1623369978580,"gmtModify":1704201760742,"author":{"id":"3570424148942091","authorId":"3570424148942091","name":"Fredwkh","avatar":"https://static.tigerbbs.com/301d103aff8ff9955978aa630ee85588","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Like and comment pls&nbsp;","listText":"Like and comment pls&nbsp;","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/181936040","repostId":1145078337,"repostType":4,"repost":{"id":"1145078337","pubTimestamp":1623369715,"share":"https://www.laohu8.com/m/news/1145078337?lang=&edition=full","pubTime":"2021-06-11 08:01","market":"us","language":"en","title":"Heat Biologics records biggest one-day gain in over four months","url":"https://stock-news.laohu8.com/highlight/detail?id=1145078337","media":"seekingalpha","summary":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a ne","content":"<ul>\n <li>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.</li>\n <li>Last week, the company updated Phase 2 data for its off-the-shelf,&nbsp;allogeneic cell therapy HS-110&nbsp;in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).</li>\n <li>In previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.</li>\n <li>mOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.</li>\n <li>“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.</li>\n <li>“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”</li>\n <li>Heat Biologics announced positive interim data&nbsp;from the trial in February.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heat Biologics records biggest one-day gain in over four months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeat Biologics records biggest one-day gain in over four months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1145078337","content_text":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, allogeneic cell therapy HS-110 in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).\nIn previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.\nmOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.\n“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.\n“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”\nHeat Biologics announced positive interim data from the trial in February.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4699218,"gmtCreate":1623457894922,"gmtModify":1663228526230,"authorId":3570424148942091,"author":{"id":3570424148942091,"authorId":3570424148942091,"name":"Fredwkh","avatar":"https://static.tigerbbs.com/301d103aff8ff9955978aa630ee85588","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181936040,"type":1,"supId":0,"prevId":0,"content":"Thanks","text":"Thanks","html":"Thanks"},{"id":4674775,"gmtCreate":1623370469515,"gmtModify":1663228408234,"authorId":3574221145623189,"author":{"id":3574221145623189,"authorId":3574221145623189,"name":"YH17","avatar":"https://static.tigerbbs.com/f600caf80ccbe52f6a8d46d71da20f19","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181936040,"type":1,"supId":0,"prevId":0,"content":"done.<br>\nplease do the same.","text":"done.<br>\nplease do the same.","html":"done.<br>\nplease do the same."}],"langContent":"EN"},{"id":181938075,"gmtCreate":1623369922397,"gmtModify":1704201759276,"author":{"id":"3572305441240915","authorId":"3572305441240915","name":"LongZR","avatar":"https://static.tigerbbs.com/80b6c7bb6866455f69d500fddb520c7e","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":5,"crmLevelSwitch":0},"htmlText":"Nice like comment","listText":"Nice like comment","text":"Nice like comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/181938075","repostId":1145078337,"repostType":4,"repost":{"id":"1145078337","pubTimestamp":1623369715,"share":"https://www.laohu8.com/m/news/1145078337?lang=&edition=full","pubTime":"2021-06-11 08:01","market":"us","language":"en","title":"Heat Biologics records biggest one-day gain in over four months","url":"https://stock-news.laohu8.com/highlight/detail?id=1145078337","media":"seekingalpha","summary":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a ne","content":"<ul>\n <li>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.</li>\n <li>Last week, the company updated Phase 2 data for its off-the-shelf,&nbsp;allogeneic cell therapy HS-110&nbsp;in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).</li>\n <li>In previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.</li>\n <li>mOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.</li>\n <li>“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.</li>\n <li>“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”</li>\n <li>Heat Biologics announced positive interim data&nbsp;from the trial in February.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heat Biologics records biggest one-day gain in over four months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeat Biologics records biggest one-day gain in over four months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3705412-heat-biologics-records-biggest-one-day-gain-in-over-four-months","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1145078337","content_text":"Recording its biggest one-day gain since early February, Heat Biologics(NASDAQ:HTBX)has reached a near four-month high today.\nLast week, the company updated Phase 2 data for its off-the-shelf, allogeneic cell therapy HS-110 in combination with Bristol Myers Squibb's checkpoint inhibitor (CPI), OPDIVO (nivolumab) in patients with non-small cell lung cancer (NSCLC).\nIn previously treated, CPI naïve patients with advanced NSCLC (Cohort A, n=47), the median overall survival ((mOS)) stood at 24.6 months.\nmOS was 11.9 months in NSCLC patients who were previously treated with CPI and whose disease had subsequently progressed (Cohort B, n=68), the company said.\n“This data further reinforces the potential utility of HS-110 in combination with a CPI for multiple treatment settings of NSCLC,” commented Jeff Wolf, CEO of Heat.\n“Our latest results, consistent with previously reported data, provide a strong foundation for the Company to discuss possible Phase 3 registration trial designs with the FDA and potential partners.”\nHeat Biologics announced positive interim data from the trial in February.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4674547,"gmtCreate":1623369942018,"gmtModify":1663228407332,"authorId":3572305441240915,"author":{"id":3572305441240915,"authorId":3572305441240915,"name":"LongZR","avatar":"https://static.tigerbbs.com/80b6c7bb6866455f69d500fddb520c7e","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181938075,"type":1,"supId":0,"prevId":0,"content":"<u>nice</u>","text":"<u>nice</u>","html":"<u>nice</u>"},{"id":4674550,"gmtCreate":1623369949607,"gmtModify":1663228403332,"authorId":3570769377369254,"author":{"id":3570769377369254,"authorId":3570769377369254,"name":"Glenna","avatar":"https://static.tigerbbs.com/8cb1540811be40c4d05341502c35498c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181938075,"type":1,"supId":0,"prevId":0,"content":"good","text":"good","html":"good"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":66,"commentSize":10,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}